Provided by Tiger Trade Technology Pte. Ltd.

Legend Biotech

17.41
-0.4600-2.57%
Post-market: 17.750.3400+1.95%19:54 EDT
Volume:1.09M
Turnover:19.28M
Market Cap:3.22B
PE:-10.75
High:18.80
Open:18.18
Low:17.38
Close:17.87
52wk High:45.30
52wk Low:16.24
Shares:184.69M
Float Shares:81.38M
Volume Ratio:0.95
T/O Rate:1.34%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.6200
EPS(LYR):-1.6200
ROE:-29.06%
ROA:-5.01%
PB:3.21
PE(LYR):-10.75

Loading ...

Legend Biotech director Tomas J. Heyman files Form 3 initial beneficial ownership statement

Reuters
·
Mar 19

Legend Biotech files Form 3 as director Meng Robin reports no beneficial ownership securities

Reuters
·
Mar 19

Legend Biotech director Casey Patrick John files initial beneficial ownership statement

Reuters
·
Mar 19

Legend Biotech CFO Carlos E Santos Files Initial Beneficial Ownership Statement

Reuters
·
Mar 19

Legend Biotech Director Corazon D. Sanders Files Initial Beneficial Ownership Statement

Reuters
·
Mar 19

Legend Biotech CEO and Director Huang Ying files initial beneficial ownership statement

Reuters
·
Mar 19

Legend Biotech files Form 3 initial beneficial ownership statement for director Wang Ye

Reuters
·
Mar 19

GENSCRIPT BIO (01548) Surges Over 5% on Strong Annual Revenue Growth and Narrowed Losses at Legend Biotech

Stock News
·
Mar 17

Legend Biotech (LEGN) Is Up 7.3% After CARVYKTI Reaches Profitability And 10,000 Patients Treated

Simply Wall St.
·
Mar 13

Legend Biotech Shares Likely to Rebound in 2026 on Robust Fundamentals, RBC Says

MT Newswires Live
·
Mar 11

Legend Biotech Is Maintained at Outperform by RBC Capital

Dow Jones
·
Mar 11

Analysts Offer Insights on Healthcare Companies: Legend Biotech (LEGN) and Medtronic (MDT)

TIPRANKS
·
Mar 11

Legend Biotech price target lowered to $49 from $50 at Morgan Stanley

TIPRANKS
·
Mar 11

Legend Biotech price target lowered to $62 from $66 at RBC Capital

TIPRANKS
·
Mar 11

Morgan Stanley Keeps Their Buy Rating on Legend Biotech (LEGN)

TIPRANKS
·
Mar 11

Legend Biotech (LEGN) Receives a Buy from Oppenheimer

TIPRANKS
·
Mar 11

RBC Capital Reaffirms Their Buy Rating on Legend Biotech (LEGN)

TIPRANKS
·
Mar 11

Piper Sandler Remains a Buy on Legend Biotech (LEGN)

TIPRANKS
·
Mar 11

RBC Cuts Price Target on Legend Biotech to $62 From $66, Keeps Outperform Rating

MT Newswires Live
·
Mar 11

Genscript Flags Legend Biotech’s 2025 Results, Cautions Investors on Risk

TIPRANKS
·
Mar 10